## David McCall

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8281287/publications.pdf

Version: 2024-02-01

14	354	8	14
papers	citations	h-index	g-index
16	16	16	619 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Programmed cell death protein blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation in an adolescent patient. Pediatric Blood and Cancer, 2022, 69, e29390.	1.5	2
2	Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients. Oncotarget, 2022, 13, 521-533.	1.8	4
3	Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers, 2022, 14, 150.	3.7	30
4	Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1176-1184.	2.5	6
5	The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. Nature Communications, 2022, 13, .	12.8	14
6	Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Therapy, 2021, 28, 1325-1338.	4.6	13
7	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nature Reviews Clinical Oncology, 2021, 18, 435-453.	27.6	31
8	Gilteritinib combination therapies in pediatric patients with <i>FLT3</i> nutated acute myeloid leukemia. Blood Advances, 2021, 5, 5215-5219.	5.2	9
9	Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities. Frontiers in Oncology, 2020, 10, 1227.	2.8	1
10	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers, 2020, 12, 1768.	3.7	20
11	Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nature Reviews Clinical Oncology, 2019, 16, 45-63.	27.6	178
12	Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma. Acta Biomaterialia, 2019, 100, 38-51.	8.3	33
13	LGG-18. GANGLIOGLIOMAS IN CHILDREN - MD ANDERSON CANCER CENTER EXPERIENCE. Neuro-Oncology, 2018, 20, i108-i108.	1.2	O
14	Pediatric ependymoma: current treatment and newer therapeutic insights. Future Oncology, 2018, 14, 3175-3186.	2.4	12